Can a top­i­cal treat­ment beat block­buster eye in­jecta­bles? A Swiss biotech has the cash now to find out

5 years ago
Financing

How much? Pfiz­er ex­pects to reap at least $26B from Covid vac­cine in 2021

5 years ago
R&D
Coronavirus

Per­son­al­ized elec­tric stim­u­la­tion for epilep­sy, de­pres­sion? Morn­ing­side bets $17.5M on an idea dat­ing back to Ro­man ...

5 years ago
Financing

Pfiz­er hits the brakes on their piv­otal tri­al for a BC­MA/CD3 bis­pe­cif­ic on safe­ty con­cerns while FDA road­block is ...

5 years ago
R&D

Covid-19 roundup: EMA be­gins rolling re­view of first Chi­nese vac­cine; Af­ter 100% ef­fi­ca­cy tri­al, teenagers could be ...

5 years ago
Coronavirus

Lil­ly's Covid-19 part­ner Ab­Cellera is tak­ing a new an­ti­body in­to the clin­ic in the hopes it can tack­le all vari­ants

5 years ago
Coronavirus

Sig­ma-Aldrich hit with $9M fine for mis­lead­ing in­fo dur­ing Mer­ck KGaA merg­er

5 years ago
Deals
FDA+

Astel­las walks away from $450M+ Cy­to­ki­net­ics pact af­ter tak­ing a few ex­tra months to see progress

5 years ago
Deals

News brief­ing: Gy­ro­scope and Ta­laris set IPO terms; FDA grants ex­pand­ed nod to Chiesi's sick­le cell drug

5 years ago
News Briefing

Stealthy Third Rock start­up poach­es on­col­o­gy ex­ec from No­var­tis — just days af­ter his boss jumped ship

5 years ago
People

Al­ny­lam pro­vides long-term look at Oxlu­mo, aim­ing to fur­ther carve out stake in PH1 mar­ket

5 years ago
R&D

ICH plots ma­jor over­haul of good clin­i­cal prac­tice guide­line

5 years ago
R&D
FDA+

Did Sarep­ta re­al­ly score a suc­cess in the lat­est cut of their next-gen Duchenne MD drug? As usu­al, that's a lit­tle ...

5 years ago
R&D

Avro­bio re­tools Fab­ry gene ther­a­py plans af­ter com­pet­ing drug's full ap­proval shuts path­way to an ac­cel­er­at­ed nod

5 years ago
Cell/Gene Tx

Covid-19 roundup: No­vavax plots EU vac­cine ship­ments by end of year — re­port; Pfiz­er pledges med­i­cines, equip­ment ...

5 years ago
Coronavirus

Alk­er­mes hands a board seat to Alex Den­ner's Saris­sa af­ter fac­ing re­newed proxy pres­sure to 're­fresh' di­rec­tors

5 years ago
People

As­traZeneca's big CKD promis­es come to fruition as Farx­i­ga wins ap­proval in pa­tients re­gard­less of di­a­betes sta­tus

5 years ago
FDA+

Vivek Ra­maswamy and Matt Gline swoop in­to Nas­daq on the wings of Jim Mom­tazee's SPAC with a $7B-plus Roivant de­but ...

5 years ago
Financing

A mus­cled up Mod­er­na fi­nal­ly joins the CO­V­AX crew, pledg­ing 500M dos­es for low-in­come coun­tries

5 years ago
Deals
Coronavirus

Qui­et end for flashy up­start, the PD-(L)1 reck­on­ing that was­n't, Big Phar­ma's Covid-19 year, and more

5 years ago
Weekly

Look­ing to rein­vent those trou­bled AAVs you've been read­ing about, in­vestors back a $110M re­boot ef­fort

5 years ago
Financing

J&J bids for EU OK on Leg­end CAR-T; FDA ex­tends re­view pe­ri­od for Arde­lyx's phos­pho­rus con­trol drug

5 years ago
News Briefing

The Covid-19 pan­dem­ic can't hold down glob­al drug spend­ing, IQVIA re­ports, with cash ex­pect­ed to keep flow­ing

5 years ago
Pharma

Bio­gen won’t ex­plain why FDA slapped down their bid for new Tysabri for­mu­la­tion

5 years ago
Pharma
FDA+
First page Previous page 698699700701702703704 Next page Last page
A service from the Financial Times